Mylan debuts generic Gleevec in USA

Netherlands-incorporated Mylan has announced the US launch of its imatinib mesylate product, a generic version of the tyrosine kinase inhibitor marketed by Novartis as Gleevec in North America and Glivec in Europe

The American generics giant joins other drugmakers, including Teva Pharmaceutical Industries and Canada’s Apotex, in the competitive imatinib market.

Mylan says it will offer a discount card providing up to $700 off the monthly out-of-pocket costs for the product, which is reusable up to 12 times per calendar year.